3 Promising Growth Stocks You Can Buy for Less Than $100

The article identifies Carnival (CCL), AstraZeneca (AZN), and Block (XYZ) as potentially undervalued growth stocks. Carnival's revenue rose 7% year-over-year to $5.8 billion, but its debt remains substantial at $25.5 billion. AstraZeneca projects annual sales to top $80 billion by 2030, with oncology products generating over $5.6 billion in Q1, and pays a dividend yielding 2.3%. Block's revenue was down 3% in Q1, but the company has grown revenue by 37% in the last three years, benefiting from both crypto popularity and economic growth.

Analysis

The article identifies Carnival (CCL), AstraZeneca (AZN), and Block (XYZ) as potentially undervalued growth stocks suitable for long-term investment. Carnival reported a 7% year-over-year revenue increase to $5.8 billion for the quarter ending February 28, with operating income nearly doubling to $543 million from $276 million a year prior. However, the company's significant long-term debt of $25.5 billion led to a net loss for the quarter, driven by $629 million in interest expenses and debt repayment costs, though it is actively addressing its debt load and trades at an estimated 13 times forward earnings. AstraZeneca is presented as a robust growth entity, projecting annual sales to exceed $80 billion by 2030, a substantial increase from $54 billion last year, supported by strong performance in its oncology division which generated over $5.6 billion in the first three months of the year. The stock's appeal is enhanced by a price/earnings-to-growth multiple below 1 and a dividend yield of 2.3%. Block (referred to as XYZ in the article for its ticker, but known as SQ) has experienced recent headwinds, with its stock down over 30% year-to-date and a 3% revenue decline in the first quarter. Despite this, Block has demonstrated significant long-term growth, with revenue expanding 37% over three years from $17.7 billion in 2021 to $24.1 billion last year, and benefits from its Cash App and merchant payment solutions, with approximately 40% of its revenue linked to Bitcoin, albeit with minimal margins; it trades at less than 16 times estimated future earnings.

Key Decisions for Investors

• Investors considering Carnival should weigh its robust operational recovery and attractive forward P/E against the substantial $25.5 billion debt burden impacting net profitability, making debt reduction progress a critical factor to monitor.
• AstraZeneca's strong sales growth projections, diverse pharmaceutical portfolio, favorable PEG ratio below 1, and consistent dividend yield present a compelling case for growth-oriented investors seeking exposure to the healthcare sector.
• For Block, investors should assess the recent stock underperformance and Q1 revenue decline in context of its significant three-year revenue growth, exposure to cryptocurrency markets, and a forward P/E multiple below the S&P 500 average, while acknowledging the stock's inherent volatility and current challenges.